Key Takeaways
- GLP-1 coverage is becoming a employee benefits strategy decision, not just a drug coverage decision. As employee demand grows and clinical applications continue to evolve, employers should consider how these therapies fit within their broader approach to health outcomes, cost management, and plan sustainability.
- There is no one-size-fits-all approach to GLP-1 coverage. The right strategy depends on an organization’s workforce demographics, claims experience, benefits philosophy, and long-term objectives. Coverage decisions are best informed by workforce data rather than market trends alone.
- Organizations that evaluate their coverage strategy proactively tend to be better positioned than those responding to rising demand after the fact. Establishing clear guidelines and ensuring benefits decisions align with both employee needs and long-term plan sustainability is where that work begins.
A 2024 Statistics Canada’s Canadian Health Measures Survey highlighted that more than two-thirds of Canadian adults aged 18 to 79 had a body mass index classified as overweight or having obesity, an increase from 60 percent before the COVID-19 pandemic. This reality is one of the reasons why GLP-1 medications such as Ozempic, Wegovy, and Mounjaro have become some of the most discussed topics in employee benefits today.
For plan sponsors, the conversation is about much more than a single category of medication. It touches on employee health, chronic disease management, rising drug costs, and the long-term sustainability of employee benefits plans.
As awareness grows and employees increasingly ask about coverage, employers are finding themselves faced with difficult questions. Should these therapies be covered? If so, under what circumstances? How can organizations balance access to treatment with responsible cost management?
The answers are rarely straightforward. What is becoming clear, however, is that GLP-1s are no longer simply a pharmacy issue. They have become a benefits strategy issue.
Why GLP-1s Are Getting So Much Attention
While medications such as Ozempic and Wegovy are often associated with weight loss, the conversation surrounding them has expanded considerably. Employers are increasingly evaluating these therapies through the lens of overall health outcomes and chronic disease management, and employee interest continues to grow.
For many plan sponsors, this has created a pressing challenge: demand is increasing faster than plan design strategies are evolving.
From Coverage Decisions to Coverage Strategies
Historically, many benefits decisions centered on a relatively simple question: should a treatment be covered or not?
GLP-1 medications have changed that conversation entirely. Few organizations are approaching this as a binary decision. Instead, they are exploring how coverage can be structured in a way that supports employee health while maintaining long-term plan sustainability.
Factors such as eligibility criteria, prior authorization, clinical oversight, and ongoing plan monitoring have become central to that process. Each one helps ensure that access is thoughtfully aligned with the benefits plan’s objectives and the genuine health needs of the workforce.
Balancing Employee Expectations and Plan Sustainability
Employees are becoming more informed about GLP-1 therapies, and many are beginning to expect access through their workplace benefits plans. At the same time, employers must manage finite benefits budgets and ensure plans remain sustainable for the entire workforce.
This tension sits at the centre of the GLP-1 discussion. Providing access to treatment and maintaining affordability are not mutually exclusive objectives, but achieving both simultaneously requires a deliberate approach. Organizations that evaluate their strategy proactively are consistently better positioned than those responding to rising demand after the fact.
What Employers Should Be Thinking About
As the conversation continues to evolve, plan sponsors should consider the following questions:
- How does current coverage align with the organization’s benefits philosophy?
- Are there clear criteria governing access to treatment?
- How will potential increases in utilization affect long-term plan costs?
- What role should clinical oversight play in coverage decisions?
- How will coverage decisions be communicated to employees?
These questions may ultimately matter more than the medications themselves.
The Role of Strategic Benefits Consulting
As benefits challenges grow more complex, many organizations are moving away from generic solutions and toward more data-driven decision making.
An experienced benefits consultant can help organizations analyze workforce demographics and claims trends, evaluate the potential impact of coverage changes, assess long-term plan sustainability, and develop communication strategies that support employee understanding. A strategic consulting partner helps employers align benefits decisions with broader organizational objectives rather than simply reacting to market trends.
Looking Ahead
GLP-1 therapies are likely to remain a significant topic in employee benefits for the foreseeable future. The organizations that navigate this issue most effectively will not necessarily be those that provide the broadest coverage or the strictest limitations. They will be the organizations that develop thoughtful, data-informed strategies that balance employee health outcomes, plan affordability, and long-term sustainability.
At Benchmark Benefits, we have spent more than two decades helping organizations across a wide range of industries evaluate complex benefits challenges and develop solutions tailored to their workforce.
To learn more about how we can support your organization’s benefits strategy, contact our team today.